In Brief: Pharmacia & Upjohn's Remisar
Executive Summary
Pharmacia & Upjohn's Remisar: NDA submitted April 30 for bropirimine 250 mg tablets for treatment of carcinoma in situ bladder cancer. Remisar will be used to treat patients intolerant to BCG therapy. Among BCG non-responders, "about a third achieved remission" in bropirimine studies, the company says...